文献速递男科与性医学

性医学学会北美成员对性腺功能减退症诊断与管理实践模式的调查

Practice Patterns in the Diagnosis and Management of Hypogonadism: A Survey of Sexual Medicine Society of North America Members.
PubMed 文献 · Urology · 2017-05-04

本研究向性医学学会北美分会全体成员发放23题问卷,调查性腺功能减退症的诊断与治疗模式,共纳入101份回复。最常用诊断阈值为300 ng/dL(55%,范围200-400 ng/dL),31%的受访者愿意对血清睾酮正常但有症状的患者给予睾酮治疗,68%会为伴有严重下尿路症状的性腺功能减退男性开具睾酮治疗,64%会为低危前列腺癌主动监测患者提供睾酮治疗。受访者中无人认为睾酮治疗增加心血管事件风险。

要点

  • 最常用诊断阈值为300 ng/dL(55%,范围200-400 ng/dL)。
  • 31%的受访者愿意对血清睾酮正常但有症状的患者给予睾酮治疗。
  • 68%会为伴严重下尿路症状的性腺功能减退男性开具睾酮治疗,64%会为低危前列腺癌主动监测患者提供睾酮治疗。

核心结论

  • 性腺功能减退症的诊断与治疗存在显著差异。
  • 多数医生仅在血清睾酮低于正常时开具睾酮治疗,尽管患者存在症状。
  • 受访医生中无人报告对心血管事件风险的担忧。

研究设计与样本

  • 向性医学学会北美分会全体成员发放23题问卷,调查性腺功能减退症的诊断与治疗。
  • 采用卡方分析比较性医学专科培训医生与非专科培训医生、学术与非学术医生之间的应答差异。
  • 共纳入101份回复进行分析。

主要发现

  • 最常用诊断阈值为300 ng/dL(55%,范围200-400 ng/dL)。
  • 31%的受访者愿意对血清睾酮正常但有症状的患者给予睾酮治疗。
  • 68%的受访者会为伴有严重下尿路症状的性腺功能减退男性开具睾酮治疗。
  • 64%的受访者会为低危前列腺癌主动监测患者提供睾酮治疗。
  • 专科培训医生更可能为性腺功能减退但血清睾酮正常的男性开具睾酮治疗(P = .038),但在希望保留或恢复生育力的性腺功能减退男性中,他们使用的治疗类型存在差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe practice patterns in the diagnosis and treatment of hypogonadism, as the optimal approaches are controversial. Multiple therapeutic options are currently available for hypogonadal men and treatment patterns vary considerably. The safety of testosterone therapy (TTh) remains understudied. MATERIALS AND METHODS: A 23-question survey regarding diagnosis and treatment of hypogonadism was sent to all members of the Sexual Medicine Society of North America. Subgroup analyses compared responses between sexual medicine fellows and non-fellows, as well as between academic and nonacademic physicians, using a chi-squared analysis. RESULTS: A total of 101 responses were included for analysis. The most common cutoff value used to diagnose hypogonadism was 300 ng/dL (55%, range = 200-400 ng/dL), and 31% felt comfortable giving TTh to a symptomatic patient with normal serum testosterone levels. No respondents felt that TTh increased a cardiovascular event risk. Of those surveyed, 68% would prescribe TTh to a hypogonadal man with severe lower urinary tract symptoms, and 64% would offer TTh to a man with low-risk prostate cancer on active surveillance. Fellowship-trained physicians were more likely to prescribe TTh to a man with hypogonadism but normal serum testosterone (P = .038), but they differed in the types of therapy they would use for men with hypogonadism who wish to preserve or regain fertility. CONCLUSION: Significant variety exists in the diagnosis and treatment of hypogonadism. The majority of physicians will only prescribe TTh in the setting of subnormal serum testosterone levels, despite the presence of symptoms. None of the surveyed physicians reported concern over the risk of cardiovascular events.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Yafi FA, Haney NM, Anaissie J, et al. Practice Patterns in the Diagnosis and Management of Hypogonadism: A Survey of Sexual Medicine Society of North America Members. Urology. 2017. PMID: 28479477. doi:10.1016/j.urology.2017.04.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。